Tactile Medical Reports Q3 2024 Financial Results

Tactile Medical (NASDAQ: TCMD), a medical technology company specializing in treatments for chronic diseases, reported a 5% increase in third-quarter revenue to $73.1 million compared to the same period last year. Both the lymphedema and Airway Clearance segments contributed to this revenue growth, and gross margins improved due to lower material costs and warranty expenses.

Despite the positive quarter, revenue fell short of expectations due to increased documentation requirements and uneven buying patterns. Tactile Medical's leadership remains optimistic, with new technology tools and policy changes seen as drivers for future growth.

Key Takeaways

• Total revenue for Q3 2024 was $73.1 million, up 5% year-over-year.
• Lymphedema business revenue increased 4.4% to $65.3 million, while Airway Clearance revenue rose 10.3% to $7.8 million.
• Gross margin improved by 410 basis points, contributing to a 39.3% increase in adjusted EBITDA.
• Revenue guidance for 2024 has been updated to $292 million to $295 million, with adjusted EBITDA guidance raised to $35 million to $37 million.
• The retirement of the current Local Coverage Determination (LCD) for pneumatic compression devices is seen as a positive development.
• A $30 million share repurchase program has been initiated, highlighting confidence in the company's growth.
• Net income and non-GAAP net income declined, with a significant rise in income tax expense due to prior year adjustments.

Company Outlook

• Tactile Medical is modernizing workflows and enhancing technology tools to address sales rep productivity challenges.
• The company expects improved sales following the shift to National Coverage Determination (NCD) policy, allowing more interpretation by Medicare Administrative Contractors (MACs).
• The upcoming launch of the new Nimbl device and strong clinical trial results for Flexitouch are anticipated to boost future growth.

Challenges and Opportunities

Bearish Highlights

• Increased documentation requirements have negatively impacted revenue particularly in the Medicare channel.
• Sales rep productivity has suffered due to these changes, resulting in lower revenue than expected.

Bullish Highlights

• Sales of AffloVest have grown year-over-year, benefiting from seasonality.
• Transition to NCD is expected to ease compliance challenges.

Q&A Highlights

• Effective management of Medicare claims backlogs indicates strong claims approval rates.
• No significant issues with Medicare claims are anticipated going forward.

Leadership Commentary

Tactile Medical's leadership, including CEO Sheri Dodd and CFO Elaine Birkemeyer, is committed to overcoming challenges while capitalizing on opportunities within the evolving policy landscape. The focus remains on operational improvements and enhancing patient access to ensure continued growth.

InvestingPro Insights

Tactile Medical's fiscal performance and outlook reveal:
– Market cap stands at $362.14 million.
– Moderate debt levels support the new $30 million repurchase program.
– Revenue grew 5.71% year-over-year, mirroring the reported revenue increase.
– The gross profit margin was 72.07%, indicating the effectiveness of cost management.

Financial Remarks

Full Transcript – Tactile Systems Technology Inc (NASDAQ: TCMD) Q3 2024

Operator: Please standby. Welcome, ladies and gentlemen, to the Third Quarter 2024 Earnings Conference Call for Tactile Medical…

Sam Bentzinger: Good afternoon, and thank you for joining the call today…

Sheri Dodd: Thanks, Sam. Good afternoon, everyone. Today, we will review our financial results for the third quarter… Total revenue in the third quarter grew 5% year-over-year to $73.1 million…

Elaine Birkemeyer: Thanks, Sheri. Total revenue in the third quarter increased by 5% to $73.1 million…

Sheri Dodd: In closing, my confidence in our team and our business remains high…

Operator: Thank you. We will now be conducting a question-and-answer session…